Review proposes gut microbiota as intermediary in GLP-1 agonist analgesia
Authors cite spinal microglial GLP-1R/interleukin-10/beta-endorphin signaling, NLRP3 inhibition and TRPV1 blockade as pain pathways largely independent of weight loss.
PR
By Priya Raman · Science Reporter
Sep 21 20:00 ETSource: Nutrients
The wire
- 01A narrative synthesis in Nutrients covering literature through June 30, 2026, links GLP-1 receptor agonists to enrichment of SCFA-producing taxa depleted in chronic pain states.
- 02Clinical evidence is described as strongest for knee osteoarthritis and idiopathic intracranial hypertension headache, with emerging signals in fibromyalgia, visceral pain and reduced opioid use.
- 03The authors state the microbiota model awaits direct confirmation in humans and call for pain-specific trials with dietary and microbiome endpoints.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 Receptor Agonists, Gut Microbiota, and Chronic Pain: Nutritional Signaling at the Gut-Brain Axis
Nutrients · 2026 Sep 22 · Odonkor CA, Dodurgali MR, Cox FR et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42884570/
